Gaucher Disease Pipeline Insights 2025 Market - 2026-2032

March 2025 | - | ID: G5FB0CFBEB7BEN
DataM Intelligence

Contents

1. EXECUTIVE SUMMARY

• Introduction

2. GAUCHER DISEASE: OVERVIEW

• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment

3. PIPELINE ANALYSIS

• Assessment by Phase
o Phase I Clinical Trials
o Phase II Clinical Trials
o Phase III Clinical Trials
• Assessment by Mechanism of Action
o Enzyme Replacement Therapy (ERT)
o Substrate Reduction Therapy (SRT)
o Gene Therapy
• Assessment by Route of Administration
o Intravenous
o Oral

4. LIST OF KEY COMPANIES INVOLVED

• CANbridge Life Sciences Ltd. *
o Drug Profile
• Spur Therapeutics
• Prevail Therapeutics
• Sanofi
• Lingyi Biotech Co., Ltd.
• Yuhan Corporation

5. REGULATORY DESIGNATIONS

• Orphan Drug Designation
• Fastrack Designation
• Breakthrough Therapy Designation
• Priority Review
• PRIME Designation
• RMAT Designation
• ATMP Designation

6. CLINICAL DATA READOUTS

• Trial Initiation
• Trial Completion
• Safety/Efficacy- Data Readouts
• Discontinued Products

7. ESTIMATED APPROVALS

8. MERGER AND ACQUISITIONS

9. FUTURE PERSPECTIVES AND CONCLUSION